» Articles » PMID: 32043613

Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2020 Feb 12
PMID 32043613
Citations 277
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Chronic hepatitis B virus (HBV), hepatitis C virus (HCV), nonalcoholic fatty liver disease (NAFLD), and alcohol-associated liver disease (ALD) are main causes of chronic liver disease. We assessed the global incidence, mortality, and disability-adjusted life-years (DALYs) related to chronic liver disease (primary liver cancer [LC] and cirrhosis).

Approach And Results: We obtained data from the 2017 Global Burden of Disease study. In 2017, there were 2.14 million liver-related deaths (2.06-2.30 million), representing an 11.4% increase since 2012 (16.0% increase in LC deaths; 8.7% increase in cirrhosis deaths). LC and cirrhosis accounted for 38.3% and 61.7%, respectively, of liver deaths (LC and cirrhosis deaths were related to HBV [39% and 29%], HCV [29% and 26%], ALD [16% and 25%], and NAFLD [8% and 9%]). Between 2012 and 2017, age-standardized incidence rate, age-standardized death rate (ASDR), and age-standardized DALY rate increased for LC from 11.1 to 11.8, 10.1 to 10.2, and 250.4 to 253.6 per 100,000, respectively. Although age-standardized incidence rate for cirrhosis increased from 66.0 to 66.3, ASDR and age-standardized DALY rate decreased from 17.1 to 16.5 and 532.9 to 510.7, respectively. The largest increase in ASDR for LC occurred in Eastern Europe (annual percent change [APC] = 2.18% [0.89%-3.49%]), whereas the largest decrease occurred in high-income Asia Pacific (APC = -2.88% [-3.58 to -2.18%]). ASDR for LC-NAFLD and ALD increased annually by 1.42% (1.00%-1.83%) and 0.53% (0.08-0.89), respectively, whereas there were no increases for HBV (P = 0.224) and HCV (P = 0.054). ASDR for cirrhosis-NAFLD increased (APC = 0.29% [0.01%-0.59%]) but decreased for ALD (APC = -0.44% [-0.78% to -0.40%]), HCV (APC = -0.50% [-0.81% to -0.18%]), and HBV (APC = -1.43% [-1.71% to -0.40%]).

Conclusions: From 2012 to 2017, the global burden of LC and cirrhosis has increased. Viral hepatitis remains the most common cause of liver deaths, and NAFLD is the most rapidly growing contributor to liver mortality and morbidity.

Citing Articles

Association of occupational physical activity and sedentary behaviour with the risk of hepatocellular carcinoma: a case-control study based on the Inpatient Clinico-Occupational Database of Rosai Hospital Group.

Nakazawa S, Fukai K, Sano K, Furuya Y, Hoshi K, Kojimahara N BMJ Open. 2025; 15(3):e092020.

PMID: 40074261 PMC: 11904348. DOI: 10.1136/bmjopen-2024-092020.


Diagnosis and Staging of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Biomarker-Directed Aptamer Panels.

Kjaer M, Jorgensen A, Fjelstrup S, Dupont D, Bus C, Eriksen P Biomolecules. 2025; 15(2).

PMID: 40001558 PMC: 11852711. DOI: 10.3390/biom15020255.


The external validation of Dallas Steatosis Index among Asian population: a useful tool for metabolic dysfunction-associated steatotic liver disease identification and prevention.

Xia M, Lu Y, Yin F, Cao Z, Yao P, Li H J Gastroenterol. 2025; .

PMID: 39994040 DOI: 10.1007/s00535-025-02220-4.


Cannabinoid-2 receptor depletion promotes non-alcoholic fatty liver disease in mice via disturbing gut microbiota and tryptophan metabolism.

Cheng W, Pei S, Wu J, Wang Y, Yang Y, Xiao M Acta Pharmacol Sin. 2025; .

PMID: 39979552 DOI: 10.1038/s41401-025-01495-w.


Quantification of liver fat deposition in obese and diabetic patients: A pilot study on the correlation with myocardium and periapical fat content.

Chen X, Wen H, Li Q, Shen L, Luo X, Zhou B Liver Res. 2025; 6(2):103-110.

PMID: 39958629 PMC: 11791804. DOI: 10.1016/j.livres.2022.05.005.